SK Chemicals’ hemophilia therapy ‘AFSTYLA’ approved in Canada
SK Chemicals(CEO Man-Hoon Park) announced on the 18th that its hemophilia treatment ‘AFSTYLA’ acquired commercialization approval from the Canadian health authorities Health Canada after the one from the U.S. FDA.
CSL Ltd. have gone through the manufacturing process development, global clinical ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
